Overview

New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Objective Primary: Determine the objective response rate in patients with advanced gallbladder treated with new Chemotherapy regimen Secondary: Determine time to progression-free survival and overall survival of patients treated with this regimen. Determine quality of life of patients treated with this regimen. Determine the toxicity of new chemotherapy regimen
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborators:
Affiliated Hospital of Qinghai University
Air Force Military Medical University, China
Capital Medical University
China Medical University, China
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Eastern Hepatobiliary Surgery Hospital
First Affiliated Hospital of Chongqing Medical University
First People's Hospital of Kunming
Fourth Military Medical University
Jilin University
LanZhou University
Peking University First Hospital
Qilu Hospital
Qilu Hospital of Shandong University
Qinghai People's Hospital
Qinghai University
Shandong Provincial Hospital
Shanghai Changzheng Hospital
Shengjing Hospital
Southwest Hospital, China
Tang-Du Hospital
The First Affiliated Hospital of Dalian Medical University
The First Affiliated Hospital of Kunming Medical College
The first clinical college of harbin medical university
The first people's hospital of Guiyang
The first people’s hospital of Guiyang
The people's hospital of Heilongjiang province
The people’s hospital of Heilongjiang province
The Second Affiliated Hospital of Harbin Medical University
Tianjin Medical University Cancer Institute and Hospital
Xi'an Central Hospital
Xuanwu Hospital, Beijing
Treatments:
Cisplatin
Epirubicin
Fluorouracil
Leucovorin
Somatostatin